Clinical trial
A Prospective, Multicenter, Single-arm, Target Value Clinical Trial to Evaluate the Efficacy and Safety of the Carotid Artery Stent System in the Treatment of Carotid Artery Stenosis
NCT07934563 is registered in ClinicalTrials.gov with Suzhou Zenith Vascular SciTech Limited as lead sponsor.
Follow this trial by email Email me the PDF
Summary
Not yet recruiting, started December 2026. Interventional study, 208 participants (estimated). Lead sponsor Suzhou Zenith Vascular SciTech Limited; China. Primary measures: Incidence of In-Stent Restenosis (ISR); Incidence of Major Adverse Events (MAE).
How it compares
119 similar trials: same condition (Carotid Stenosis) and phase
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Multicenter, Single-arm, Target Value Clinical Trial to Evaluate the Efficacy and Safety of the Carotid Artery Stent System in the Treatment of Carotid Artery Stenosis
- Lead sponsor
- Suzhou Zenith Vascular SciTech Limited
- Phase
- Not applicable
- Overall status
- Not yet recruiting
- Start date
- December 1, 2026
- Completion date
- December 1, 2028
- Enrollment
- 208 (estimated)
- Sites
- 1
Conditions
MeSH condition names; the registry's own terms follow.
Atherosclerosis, Carotid Stenosis
Registry terms: carotid artery stenosis, carotid artery stenosis asymptomatic
Who could take part, where it ran, who ran it
As filed in ClinicalTrials.gov.
- Sex
- All
- Minimum age
- 18 Years
- Healthy volunteers
- No
- Study type
- Interventional
- Sites
- 1
- Countries
- China
- Lead sponsor
- Suzhou Zenith Vascular SciTech Limited
Arms
As registered; 1 arm.
| Arm | Type | Interventions |
|---|---|---|
| Carotid Artery Stent System | Experimental | Carotid Artery Stenting |
Primary endpoints
Registered primary outcome measures; 2 primary.
| Measure | Time frame |
|---|---|
| Incidence of In-Stent Restenosis (ISR) | through study completion, an average of 1 year |
Show registry wordingRestenosis is defined as ≥50% diameter stenosis occurring within the stent or within 5 mm of the proximal or distal stent edge of the target carotid artery, as assessed by carotid duplex ultrasound (DUS). | |
| Incidence of Major Adverse Events (MAE) | through study completion, an average of 1 year |
Show registry wordingMajor adverse events (MAE) are defined as the composite incidence of: (1) death, stroke (ischemic or hemorrhagic), or myocardial infarction (MI) occurring within 30 days after the procedure; and (2) death or ipsilateral ischemic stroke of the target vessel occurring from 31 to 365 days after the procedure. | |
Lead sponsor's other trials
Suzhou Zenith Vascular SciTech Limited, most recent start first.
Similar trials
Same condition (Carotid Stenosis) and phase, most recent start first.
+114 more trials See the condition page